サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1790442

ライソゾーム病治療市場規模、シェア、動向分析レポート：治療タイプ別、疾患タイプ別、地域別、セグメント別予測、2025年～2033年

Lysosomal Storage Disease Treatment Market Size, Share & Trends Analysis Report By Treatment Type (Enzyme Replacement Therapy, Substrate Reduction Therapy), By Disease Type, By Region, And Segment Forecasts, 2025 - 2033

出版日
ページ情報
英文 150 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=149.53円
ライソゾーム病治療市場規模、シェア、動向分析レポート：治療タイプ別、疾患タイプ別、地域別、セグメント別予測、2025年～2033年
出版日: 2025年07月01日
発行: Grand View Research
ページ情報: 英文 150 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

ライソゾーム病治療市場サマリー

ライソゾーム病治療の世界市場規模は、2024年に45億4,000万米ドルと推定され、診断能力の向上、酵素補充療法・遺伝子治療の進歩、希少遺伝性疾患に対する認知度の向上などを背景に、2025年から2033年にかけてCAGR 4.54%で成長し、2033年には66億8,000万米ドルに達すると予測されます。ライソゾーム病（LSD）治療市場は、研究開発イニシアチブの拡大と希少遺伝子疾患に対する認知度の向上により、着実な成長を遂げています。

研究開発への多額の投資によって治療法の進歩が促進され、アンメットメディカルニーズへの対応に役立っています。米国国立医学図書館が2022年7月に発表した研究によると、LSDはこれまで考えられていたよりも有病率が高く、総発症率は5,000人に1人から8,000人に1人とされています。また、民族や地域が有病率に及ぼす影響も強調されています。例えば、ゴーシェ病は一般人口では4万人から6万人に1人の割合で発症するが、アシュケナージユダヤ人では800人に1人にまで増加します。同様に、テイサックス病とニーマンピックA型はこの層で多く、アスパルチルグルコサミン尿症はフィンランド人で1万8,500人に1人と頻度が高いです。こうした有病率の上昇は、効果的な治療に対するニーズの高まりを裏付けるものであり、市場の拡大に拍車をかけています。

革新的な治療法の導入により、LSD治療市場はさらに強化されると予想されます。企業は世界の研究開発費の増加に支えられ、新薬開発を積極的に進めています。例えば、2021年2月、Genethon社はSpark Therapeutics社と共同で、独自技術を活用した遅発性ポンペ病をターゲットとする遺伝子治療臨床試験を開始しました。これと並行して、啓発キャンペーンも勢いを増し、患者の予後改善に重要な役割を果たしています。米国や英国などの国々では、全米ファブリー病財団（NFDF）、ファブリー国際ネットワーク、ファブリー・オーストラリア、英国のMPS協会が推進する毎年4月の「ファブリー病啓発月間」などの取り組みを通じて、ファブリー病に対する認識が著しく高まっています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 ライソゾーム病（LSD）治療市場の変数、動向、範囲

  • 市場系統の見通し
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • ビジネス環境分析
    • 業界分析- ポーターのファイブフォース分析
    • PESTLE分析
    • パイプライン分析
    • 特許満了分析
    • 価格分析

第4章 ライソゾーム病（LSD）治療市場：治療タイプ別ビジネス分析

  • 治療タイプの市場シェア、2025年と2033年
  • 治療タイプセグメントダッシュボード
  • 市場規模、予測、動向分析（治療タイプ別、2021～2033年）
  • 酵素補充療法
  • 基質還元療法

第5章 ライソゾーム病（LSD）治療市場：疾患タイプ別ビジネス分析

  • 疾患タイプ別市場シェア、2025年および2033年
  • 疾患タイプセグメントダッシュボード
  • 市場規模と予測および動向分析（疾患タイプ別、2021～2033年）
  • ゴーシェ病
  • ムコ多糖症
  • ポンペ病
  • ファブリー病
  • その他

第6章 ライソゾーム病（LSD）治療市場：地域推定・動向分析

  • 地域別市場シェア分析、2025年および2033年
  • 地域市場ダッシュボード
  • 市場規模と予測動向分析、2021～2033年：
  • 北米
    • 国別、2021年～2033年
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • デンマーク
    • スウェーデン
    • ノルウェー
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • オーストラリア
    • 韓国
    • タイ
  • ラテンアメリカ
    • ブラジル
    • アルゼンチン
  • 中東およびアフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第7章 競合情勢

  • 参加者概要
  • 企業の市況分析
  • 企業分類
  • 戦略マッピング
  • 企業プロファイル/上場企業
    • Pfizer Inc
    • Takeda Pharmaceutical Company Limited（Shire Plc）
    • Sanofi（Genzyme Corporation）
    • BioMarin
    • Johnson &Johnson（Actelion Pharmaceuticals Ltd）
    • Amicus Therapeutics, Inc
    • Alexion Pharmaceuticals, Inc
    • Sigilon Therapeutics, Inc
    • Orphazyme A/S
図表

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global lysosomal storage disease (LSDs) treatment market, by region, 2021 - 2033 (USD Million)
  • Table 4 Global lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 5 Global lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
  • Table 6 North America lysosomal storage disease (LSDs) treatment market, by country, 2021 - 2033 (USD Million)
  • Table 7 North America lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 8 North America lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
  • Table 9 U.S. lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 10 U.S. lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
  • Table 11 Canada lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 12 Canada lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
  • Table 13 Mexico lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 14 Mexico lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
  • Table 15 Europe lysosomal storage disease (LSDs) treatment market, by country, 2021 - 2033 (USD Million)
  • Table 16 Europe lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 17 Europe lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
  • Table 18 UK lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 19 UK lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
  • Table 20 Germany lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 21 Germany lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
  • Table 22 France lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 23 France lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
  • Table 24 Italy lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 25 Italy lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
  • Table 26 Spain lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 27 Spain lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
  • Table 28 Norway lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 29 Norway lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
  • Table 30 Denmark lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 31 Denmark lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
  • Table 32 Sweden lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 33 Sweden lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
  • Table 34 Asia Pacific lysosomal storage disease (LSDs) treatment market, by country, 2021 - 2033 (USD Million)
  • Table 35 Asia Pacific lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 36 Asia Pacific lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
  • Table 37 Japan lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 38 Japan lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
  • Table 39 China lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 40 China lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
  • Table 41 India lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 42 India lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
  • Table 43 Australia lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 44 Australia lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
  • Table 45 South Korea lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 46 South Korea lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
  • Table 47 Thailand lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 48 Thailand lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
  • Table 49 Latin America lysosomal storage disease (LSDs) treatment market, by country, 2021 - 2033 (USD Million)
  • Table 50 Latin America lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 51 Latin America lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
  • Table 52 Brazil lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 53 Brazil lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
  • Table 54 Argentina lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 55 Argentina lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
  • Table 56 Middle East & Africa Lysosomal storage disease (LSDs) treatment market, by country, 2021 - 2033 (USD Million)
  • Table 57 Middle East & Africa lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 58 Middle East & Africa lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
  • Table 59 South Africa lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 60 South Africa lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
  • Table 61 Saudi Arabia lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 62 Saudi Arabia lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
  • Table 63 UAE lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 64 UAE lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
  • Table 65 Kuwait lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 66 Kuwait lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Lysosomal storage disease (LSDs) treatment market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapeutic approach and disease type outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Lysosomal storage disease (LSDs) treatment market dynamics
  • Fig. 12 Lysosomal storage disease (LSDs) treatment market: Porter's five forces analysis
  • Fig. 13 Lysosomal storage disease (LSDs) treatment market: PESTLE analysis
  • Fig. 14 Treatment Type market, 2021 - 2033 (USD Million)
  • Fig. 15 Enzyme Replacement Therapy market, 2021 - 2033 (USD Million)
  • Fig. 16 Velaglucerase Alfa market, 2021 - 2033 (USD Million)
  • Fig. 17 Alglucosidase Alfa (Myozyme/Lumizyme) market, 2021 - 2033 (USD Million)
  • Fig. 18 Idursulfase (Elaprase) market, 2021 - 2033 (USD Million)
  • Fig. 19 Imiglucerase (Cerezyme) market, 2021 - 2033 (USD Million)
  • Fig. 20 Others market, 2021 - 2033 (USD Million)
  • Fig. 21 Substrate reduction therapy market, 2021 - 2033 (USD Million)
  • Fig. 22 Others market, 2021 - 2033 (USD Million)
  • Fig. 23 Disease Type market, 2021 - 2033 (USD Million)
  • Fig. 24 Gaucher disease market, 2021 - 2033 (USD Million)
  • Fig. 25 Mucopolysaccharidoses market, 2021 - 2033 (USD Million)
  • Fig. 26 Pompe disease market, 2021 - 2033 (USD Million)
  • Fig. 27 Fabry disease market, 2021 - 2033 (USD Million)
  • Fig. 28 Others market, 2021 - 2033 (USD Million)
  • Fig. 29 Lysosomal storage disease (LSDs) treatment market revenue, by region
  • Fig. 30 Regional marketplace: Key takeaways
  • Fig. 31 North America lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
  • Fig. 32 U.S. country dynamics
  • Fig. 33 U.S. lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
  • Fig. 34 Canada country dynamics
  • Fig. 35 Canada lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
  • Fig. 36 Mexico country dynamics
  • Fig. 37 Mexico lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
  • Fig. 38 Europe lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
  • Fig. 39 UK country dynamics
  • Fig. 40 UK lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
  • Fig. 41 Germany country dynamics
  • Fig. 42 Germany lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
  • Fig. 43 France country dynamics
  • Fig. 44 France lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
  • Fig. 45 Italy country dynamics
  • Fig. 46 Italy lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
  • Fig. 47 Spain country dynamics
  • Fig. 48 Spain lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
  • Fig. 49 Norway country dynamics
  • Fig. 50 Norway lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
  • Fig. 51 Sweden country dynamics
  • Fig. 52 Sweden lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
  • Fig. 53 Denmark country dynamics
  • Fig. 54 Denmark lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
  • Fig. 55 Asia Pacific lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
  • Fig. 56 Japan country dynamics
  • Fig. 57 Japan lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
  • Fig. 58 China country dynamics
  • Fig. 59 China lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
  • Fig. 60 India country dynamics
  • Fig. 61 India lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
  • Fig. 62 Australia country dynamics
  • Fig. 63 Australia lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
  • Fig. 64 South Korea country dynamics
  • Fig. 65 South Korea lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
  • Fig. 66 Thailand country dynamics
  • Fig. 67 Thailand lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
  • Fig. 68 Latin America lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
  • Fig. 69 Brazil country dynamics
  • Fig. 70 Brazil lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
  • Fig. 71 Argentina country dynamics
  • Fig. 72 Argentina lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
  • Fig. 73 MEA lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
  • Fig. 74 South Africa country dynamics
  • Fig. 75 South Africa lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
  • Fig. 76 Saudi Arabia country dynamics
  • Fig. 77 Saudi Arabia lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
  • Fig. 78 UAE country dynamics
  • Fig. 79 UAE lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
  • Fig. 80 Kuwait country dynamics
  • Fig. 81 Kuwait lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
  • Fig. 82 Company categorization
  • Fig. 83 Company market position analysis
  • Fig. 84 Strategic framework
目次
Product Code: GVR-4-68040-649-3

Lysosomal Storage Disease Treatment Market Summary

The global lysosomal storage disease treatment market size was estimated at USD 4.54 billion in 2024 and is projected to reach USD 6.68 billion by 2033, growing at a CAGR of 4.54% from 2025 to 2033, driven by rising diagnostic capabilities, advancements in enzyme replacement and gene therapies, and increased awareness of rare genetic disorders. The lysosomal storage disease (LSD) treatment market is experiencing steady growth due to expanding research and development initiatives and rising awareness about these rare genetic conditions.

Significant R&D investments have enhanced therapeutic advancements, helping address unmet medical needs. A study published by the National Library of Medicine in July 2022 noted that LSDs, as a group, are more prevalent than previously assumed, with a collective incidence ranging from 1 in 5,000 to 1 in 8,000 individuals. It also highlighted the influence of ethnicity and geography on disease prevalence. For instance, Gaucher disease appears in 1 in 40,000 to 60,000 people in the general population, while the rate increases to 1 in 800 among Ashkenazi Jews. Similarly, Tay-Sachs disease and Niemann-Pick A are more common in this demographic, while the Finnish population has a higher frequency of aspartylglucosaminuria at 1 in 18,500. These rising prevalence rates underscore the growing need for effective treatments, fueling market expansion.

The introduction of innovative therapies is expected to strengthen the LSD treatment market further. Companies actively pursue novel drug development, supported by increasing global R&D spending. For example, in February 2021, Genethon initiated a gene therapy clinical trial targeting late-onset Pompe disease in collaboration with Spark Therapeutics, utilizing proprietary technologies. In parallel, awareness campaigns have gained momentum, playing a vital role in improving patient outcomes. In countries like the U.S. and the UK, awareness of Fabry disease has significantly increased through initiatives like Fabry Disease Awareness Month, observed every April, as promoted by the National Fabry Disease Foundation (NFDF), Fabry International Network, Fabry Australia, and the UK's MPS Society.

Global Lysosomal Storage Disease Treatment Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global lysosomal storage disease treatment market report based on treatment type, disease type, and region:

  • Treatment Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Enzyme Replacement Therapy
    • Velaglucerase Alfa
    • Alglucosidase Alfa (Myozyme/Lumizyme)
    • Idursulfase (Elaprase)
    • Imiglucerase (Cerezyme)
    • Others
  • Substrate Reduction Therapy
  • Others
  • Disease Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Gaucher Disease
  • Mucopolysaccharidoses
  • Pompe Disease
  • Fabry Disease
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Treatment Type
    • 1.2.2. Disease Type
    • 1.2.3. Regional
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Lysosomal Storage Disease (LSDs) Treatment Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Lysosomal Storage Disease (LSDs) Treatment Market: Treatment Type Business Analysis

  • 4.1. Treatment Type Market Share, 2025 & 2033
  • 4.2. Treatment Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Treatment Type, 2021 to 2033 (USD Million)
  • 4.4. Enzyme Replacement Therapy
    • 4.4.1. Enzyme Replacement Therapy Market, 2021 - 2033 (USD Million)
    • 4.4.2. Velaglucerase Alfa
      • 4.4.2.1. Velaglucerase Alfa Market, 2021 - 2033 (USD Million)
    • 4.4.3. Alglucosidase Alfa (Myozyme/Lumizyme)
      • 4.4.3.1. Alglucosidase Alfa (Myozyme/Lumizyme) Market, 2021 - 2033 (USD Million)
    • 4.4.4. Idursulfase (Elaprase)
      • 4.4.4.1. Idursulfase (Elaprase) Market, 2021 - 2033 (USD Million)
    • 4.4.5. Imiglucerase (Cerezyme)
      • 4.4.5.1. Imiglucerase (Cerezyme) Market, 2021 - 2033 (USD Million)
    • 4.4.6. Others
      • 4.4.6.1. Others Market, 2021 - 2033 (USD Million)
  • 4.5. Substrate Reduction Therapy
    • 4.5.1. Substrate Reduction Therapy Market, 2021 - 2033 (USD Million)
    • 4.5.2. Others Market, 2021 - 2033 (USD Million)

Chapter 5. Lysosomal Storage Disease (LSDs) Treatment Market: Disease Type Business Analysis

  • 5.1. Disease Type Market Share, 2025 & 2033
  • 5.2. Disease Type Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Disease Type, 2021 to 2033 (USD Million)
  • 5.4. Gaucher Disease
    • 5.4.1. Gaucher Disease Market, 2021 - 2033 (USD Million)
  • 5.5. Mucopolysaccharidoses
    • 5.5.1. Mucopolysaccharidoses Market, 2021 - 2033 (USD Million)
  • 5.6. Pompe Disease
    • 5.6.1. Pompe Disease Market, 2021 - 2033 (USD Million)
  • 5.7. Fabry Disease
    • 5.7.1. Fabry Disease Market, 2021 - 2033 (USD Million)
  • 5.8. Others
    • 5.8.1. Others Market, 2021 - 2033 (USD Million)

Chapter 6. Lysosomal Storage Disease (LSDs) Treatment Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2025 & 2033
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 6.4. North America
    • 6.4.1. North America Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Target Disease Type Prevalence
      • 6.4.2.3. Regulatory Framework
      • 6.4.2.4. Reimbursement Framework
      • 6.4.2.5. U.S. Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Target Disease Type Prevalence
      • 6.4.3.3. Regulatory Framework
      • 6.4.3.4. Reimbursement Framework
      • 6.4.3.5. U.S. Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Target Disease Type Prevalence
      • 6.4.4.3. Regulatory Framework
      • 6.4.4.4. Reimbursement Framework
      • 6.4.4.5. Mexico Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Target Disease Type Prevalence
      • 6.5.2.3. Regulatory Framework
      • 6.5.2.4. Reimbursement Framework
      • 6.5.2.5. Uk Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Target Disease Type Prevalence
      • 6.5.3.3. Regulatory Framework
      • 6.5.3.4. Reimbursement Framework
      • 6.5.3.5. Germany Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Target Disease Type Prevalence
      • 6.5.4.3. Regulatory Framework
      • 6.5.4.4. Reimbursement Framework
      • 6.5.4.5. France Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Target Disease Type Prevalence
      • 6.5.5.3. Regulatory Framework
      • 6.5.5.4. Reimbursement Framework
      • 6.5.5.5. Italy Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Target Disease Type Prevalence
      • 6.5.6.3. Regulatory Framework
      • 6.5.6.4. Reimbursement Framework
      • 6.5.6.5. Spain Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.7. Denmark
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Target Disease Type Prevalence
      • 6.5.7.3. Regulatory Framework
      • 6.5.7.4. Reimbursement Framework
      • 6.5.7.5. Denmark Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.8. Sweden
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Target Disease Type Prevalence
      • 6.5.8.3. Regulatory Framework
      • 6.5.8.4. Reimbursement Framework
      • 6.5.8.5. Sweden Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.9. Norway
      • 6.5.9.1. Key Country Dynamics
      • 6.5.9.2. Target Disease Type Prevalence
      • 6.5.9.3. Regulatory Framework
      • 6.5.9.4. Reimbursement Framework
      • 6.5.9.5. Norway Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Target Disease Type Prevalence
      • 6.6.2.3. Regulatory Framework
      • 6.6.2.4. Reimbursement Framework
      • 6.6.2.5. Japan Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Target Disease Type Prevalence
      • 6.6.3.3. Regulatory Framework
      • 6.6.3.4. Reimbursement Framework
      • 6.6.3.5. China Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Target Disease Type Prevalence
      • 6.6.4.3. Regulatory Framework
      • 6.6.4.4. Reimbursement Framework
      • 6.6.4.5. India Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.5. Australia
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Target Disease Type Prevalence
      • 6.6.5.3. Regulatory Framework
      • 6.6.5.4. Reimbursement Framework
      • 6.6.5.5. Australia Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.6. South Korea
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Target Disease Type Prevalence
      • 6.6.6.3. Regulatory Framework
      • 6.6.6.4. Reimbursement Framework
      • 6.6.6.5. South Korea Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.7. Thailand
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Target Disease Type Prevalence
      • 6.6.7.3. Regulatory Framework
      • 6.6.7.4. Reimbursement Framework
      • 6.6.7.5. Thailand Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Target Disease Type Prevalence
      • 6.7.2.3. Regulatory Framework
      • 6.7.2.4. Reimbursement Framework
      • 6.7.2.5. Japan Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Target Disease Type Prevalence
      • 6.7.3.3. Regulatory Framework
      • 6.7.3.4. Reimbursement Framework
      • 6.7.3.5. China Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8. Middle East and Africa
    • 6.8.1. Middle East and Africa Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2017 - 2033 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Target Disease Type Prevalence
      • 6.8.2.3. Regulatory Framework
      • 6.8.2.4. Reimbursement Framework
      • 6.8.2.5. South Africa Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Target Disease Type Prevalence
      • 6.8.3.3. Regulatory Framework
      • 6.8.3.4. Reimbursement Framework
      • 6.8.3.5. Saudi Arabia Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Target Disease Type Prevalence
      • 6.8.4.3. Regulatory Framework
      • 6.8.4.4. Reimbursement Framework
      • 6.8.4.5. UAE Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Target Disease Type Prevalence
      • 6.8.5.3. Regulatory Framework
      • 6.8.5.4. Reimbursement Framework
      • 6.8.5.5. Kuwait Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. Pfizer Inc
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Treatment Type Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. Takeda Pharmaceutical Company Limited (Shire Plc)
      • 7.5.2.1. Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Treatment Type Benchmarking
      • 7.5.2.4. Strategic Initiatives
    • 7.5.3. Sanofi (Genzyme Corporation)
      • 7.5.3.1. Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Treatment Type Benchmarking
      • 7.5.3.4. Strategic Initiatives
    • 7.5.4. BioMarin
      • 7.5.4.1. Overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Treatment Type Benchmarking
      • 7.5.4.4. Strategic Initiatives
    • 7.5.5. Johnson & Johnson (Actelion Pharmaceuticals Ltd)
      • 7.5.5.1. Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Treatment Type Benchmarking
      • 7.5.5.4. Strategic Initiatives
    • 7.5.6. Amicus Therapeutics, Inc
      • 7.5.6.1. Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Treatment Type Benchmarking
      • 7.5.6.4. Strategic Initiatives
    • 7.5.7. Alexion Pharmaceuticals, Inc
      • 7.5.7.1. Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Treatment Type Benchmarking
      • 7.5.7.4. Strategic Initiatives
    • 7.5.8. Sigilon Therapeutics, Inc
      • 7.5.8.1. Overview
      • 7.5.8.2. Financial Performance
      • 7.5.8.3. Treatment Type Benchmarking
      • 7.5.8.4. Strategic Initiatives
    • 7.5.9. Orphazyme A/S
      • 7.5.9.1. Overview
      • 7.5.9.2. Financial Performance
      • 7.5.9.3. Treatment Type Benchmarking
      • 7.5.9.4. Strategic Initiatives